%PDF-1.4
%
54 0 obj
<>
endobj
51 0 obj
<>
endobj
109 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2003-11-07T16:09:40Z
2024-03-19T00:37:54-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-19T00:37:54-07:00
application/pdf
Heather
2002-928.dec
uuid:880a5591-1dd2-11b2-0a00-a208277d8900
uuid:880a5593-1dd2-11b2-0a00-d30000000000
endstream
endobj
40 0 obj
<>
endobj
41 0 obj
<>
endobj
55 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 26 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 28 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 30 0 R/Type/Page>>
endobj
17 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 32 0 R/Type/Page>>
endobj
20 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 34 0 R/Type/Page>>
endobj
127 0 obj
[131 0 R]
endobj
128 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 74.4 714.5293 Tm
(Index. J Rheumatol 1994;21:2286-91.)Tj
-2.175 -1.25 Td
[(27.)-875.1 (Calin )54.8 (A, Garrett S, )17.7 (Whitelock H, et al. )54.8 (A)-220.1 (new approach to defining)]TJ
2.175 -1.25 Td
(functional ability in ankylosing spondylitis: the development of the)Tj
0 -1.25 TD
[(Bath )54.8 (Ankylosing Spondylitis Functional Index. J Rheumatol)]TJ
0 Tc 0 Tw T*
(1994;21:2281-5. )Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(28.)-875.1 (Anderson JJ, Baron G, van der Heijde D, Felson DT)73.9 (, Dougados M.)]TJ
2.175 -1.25 Td
[(Ankylosing Spondylitis )54.8 (Assessment Group preliminary definition)]TJ
T*
[(of short-term improvement in ankylosing spondylitis. )54.8 (Arthritis)]TJ
0 Tc T*
(Rheum 2001;44:1876-86.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(29.)-875.1 (Calabrese L, Fleischer )54.8 (AB. )17.7 (Thalidomide: current and potential )]TJ
2.175 -1.25 Td
[(clinical applications. )54.8 (Am J Med 2000;108:487-95.)]TJ
30.825 12.5 Td
[(30.)-875.1 (Marriott JB, Muller G, Dalgleish )54.8 (AG. )17.7 (Thalidomide as an emer)17.7 (ging)]TJ
2.175 -1.25 Td
[(immunotherapeutic agent. Immunol )17.7 (T)69.9 (oday 1999;20:538-40. )]TJ
-2.175 -1.25 Td
[(31.)-875.1 (Klausner JD, Freedman )17.7 (VH, Kaplan G. )17.7 (Thalidomide as an )]TJ
2.175 -1.25 Td
(anti-TNF-alpha inhibitor: implications for clinical use. Clin)Tj
T*
(Immunol Immunopathol 1996;81:219-23.)Tj
-2.175 -1.25 Td
[(32.)-875.1 (D\325Amato RJ, Loughman MS, Flynn E, Folkman J. )17.7 (Thalidomide is)]TJ
2.175 -1.25 Td
[(an inhibitor of angiogenesis. Proc Nat )54.8 (Acad Sci USA)]TJ
0 Tc 0 Tw T*
(1994;91:4082-5.)Tj
ET
0 0 0 1 K
54 54 m
558 54 l
S
BT
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 54.5 35.9844 Tm
[(W)91.9 (ei, et al: Thalidomide for )17.7 (AS)]TJ
0 Tc 0 Tw 60.9375 -0.0313 Td
(2631)Tj
ET
0 0 0 0 k
/GS0 gs
109.22 59.09 396.48 -10.84 re
f*
0.5 w
109.22 59.09 396.48 -10.84 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_2 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2003. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_3 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 19, 2024 from )Tj
ET
endstream
endobj
34 0 obj
<>stream
8;Z\r$P%e3&4H9l(Yn=U]?K8L_c$!oX/f)VM42&_J
R!#PI6aibg:RRL+eN=qAej/IT9MG8o[0KmC;Km&rN8J()!om>OUQ$.DS[-sVi
];H1oYZ7"oZ03)QEG=WcC9gho+#i.?e@To`[-kO51\kC_oB%+nW&XhXzz#M==!QlJ*2
W\.2-p\D^GKuX2g5@P<~>
endstream
endobj
38 0 obj
[/Indexed/DeviceRGB 255 37 0 R]
endobj
37 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
61 0 obj
<>
endobj
58 0 obj
<>
endobj
98 0 obj
<>
endobj
114 0 obj
<>
endobj
57 0 obj
<>
endobj
91 0 obj
<>stream
HUiPSY~/<#۔CDdFDAYlQ"D IBBd b H..#*:mw3ݓҗhϟ1uN:瞯w~q|FH'BEDRMT5cqfM03fwb-r";90|'wC;q:zꊑ8N5t["X+Pde{'X,?eD B!ҤM{%Y(Q(
>JY"(+б@,$dY d T.)2D
Œ,^' Ybߵpn7lsqfgl)qĶLVه°kkBE0d =YɹJSKŎ̟"rjNNiv*;Lϟnur!\4Ѯ/݂ݘ}:pwv掙_SQ#gO\ePM=[9'|h%;L^6G|^?8y^_YhnvĪSVk*tu=-w;ٸC
%0n8\2CYH8YV1^-(
ݙ,I}\,-UWj(\{c2rKb6YyAv]
uǃ7Q#xsUɥ![4ZUJW~>pYnm+Id T$^Ps|n!lPENHΆ;䖙 k@]vA2>40
O\R !'t
jDI"J9*T
&Fsw"XQjB1)'!3SRۂ(ny9ex6!ҫȮζ3yaO?fͻõGնtr<%ӳ;͙ۤʈLFQn0W+I#I')uͧ{yrr (W3>
F]̾u}8?\Yj^N=wyi{<,ggMQ"
rm^Ku[.|rŒX['| &NQ\itVUk%^
N ~Wܮull
'fB;!